22.86

1.12% -0.26

Zymeworks Inc. (ZYME)

Overview News Price History Option Chain Discussions Forecast

Zymeworks Inc. stock is traded at $22.86, with a volume of 272.31K. It is down -1.12% in the last 24 hours and down -5.93% over the past month. Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Previous Close:

$23.12

Open:

$23.32

24h Volume:

272.31K

Relative Volume:

0.43

Market Cap:

$1.68B

Revenue:

$81.26M

Net Income/Loss:

$-102.66M

P/E Ratio:

-16.71

EPS:

-1.3678

Net Cash Flow:

$-77.62M

1W Performance:

-5.50%

1M Performance:

-5.93%

6M Performance:

-1.64%

1Y Performance:

+63.17%

1-Day Range:

$22.72

$23.69

1-Week Range:

$22.72

$24.54

52-Week Range:

$11.51

$29.75

Zymeworks Inc. Stock (ZYME) Company Profile

Name

Zymeworks Inc.

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

604-678-1388

Address

1385 West 8th Avenue, Suite 540, Vancouver, BC

Employee

170

Twitter

@ZymeworksInc

Next Earnings Date

2026-08-06

Latest SEC Filings

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZYME Zymeworks Inc.	22.86	1.68B	81.26M	-102.66M	-77.62M	-1.3678
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Oct-24-25	Resumed	Wells Fargo	Equal Weight
Oct-14-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-10-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	TD Cowen	Buy
Dec-16-24	Upgrade	JP Morgan	Neutral → Overweight
Nov-07-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-01-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-21-23	Resumed	Wells Fargo	Overweight
Jan-04-23	Reiterated	H.C. Wainwright	Neutral
Dec-20-22	Upgrade	Jefferies	Hold → Buy
Nov-01-22	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-21-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-04-22	Resumed	Wells Fargo	Overweight
May-05-22	Upgrade	Guggenheim	Neutral → Buy
Mar-15-22	Initiated	Evercore ISI	Outperform
Dec-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-17-21	Resumed	Guggenheim	Neutral
Oct-07-21	Initiated	Jefferies	Hold
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-25-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Feb-08-21	Resumed	H.C. Wainwright	Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-06-20	Initiated	SVB Leerink	Outperform
Jan-10-20	Initiated	Wolfe Research	Outperform
Dec-09-19	Initiated	JP Morgan	Neutral
Nov-25-19	Initiated	H.C. Wainwright	Buy
Nov-20-19	Initiated	Guggenheim	Buy
Sep-30-19	Upgrade	Raymond James	Outperform → Strong Buy
Aug-30-19	Initiated	Stifel	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
May-11-18	Upgrade	Barclays	Underweight → Equal Weight
Mar-19-18	Initiated	Raymond James	Outperform

View All

Zymeworks Inc. Stock (ZYME) Latest News

Jul 17, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm

Jul 17, 2026

Jul 16, 2026

Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade

Jul 16, 2026

Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative

Jul 16, 2026

Zymeworks to report Q2 2026 results on August 6, no earnings call due to Theravance Biopharma acquisition plans - Pluang

Jul 16, 2026

Jul 15, 2026

Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance

Jul 15, 2026

Jul 14, 2026

ETFs Investing in Zymeworks Inc. Stocks - TradingView

Jul 14, 2026

Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME - MarketBeat

Jul 14, 2026

Jul 13, 2026

Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME - MarketBeat

Jul 13, 2026

Jul 08, 2026

Theravance stock down 3% after Zymeworks announces buyout - MSN

Jul 08, 2026

Jul 07, 2026

Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - Ad-hoc-news.de

Jul 07, 2026

Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de

Jul 07, 2026

Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha

Jul 07, 2026

Jul 06, 2026

Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan

Jul 06, 2026

Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Jul 06, 2026

Jul 05, 2026

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI

Jul 05, 2026

Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com

Jul 05, 2026

Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et

Jul 05, 2026

Jul 03, 2026

Enterprise value to EBIT forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Jul 03, 2026

Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - Ad-hoc-news.de

Jul 03, 2026

Jul 01, 2026